Pharma

Drug delivery startup using 3D printer to produce nanodose wafers

Three dimensional printing technology has been popping up in so many places, from drug development to artificial organs of the future. A pharmaceutical startup has raised $4 million, according to documents filed with the Securities and Exchange Commission, to advance the its 3D printer technology for a more efficient way to distribute medication in the […]

Three dimensional printing technology has been popping up in so many places, from drug development to artificial organs of the future. A pharmaceutical startup has raised $4 million, according to documents filed with the Securities and Exchange Commission, to advance the its 3D printer technology for a more efficient way to distribute medication in the body.

Aprecia Pharmaceuticals in Langhorne, Pennsylvania uses the 3D technology developed at MIT for its zip dose drug delivery system. Using a 3D printer, it produces oral wafers, which can be dispersed in less than five seconds and deliver a dosage loading of more than 50 mg, according to Ben Franklin Technology Partners of Southeastern Pennsylvania’s website. It also offers a “nano dose” that the company claims is a low dosage drug delivery with precision and accuracy. It also has biodegradable  implants, according to its website.

Last year, Aprecia raised $25.7 million.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

It’s estimated that the drug delivery market will rise to $199 billion by 2016 according to GBI Research, as patent losses spur pharmaceutical companies to position and reformulate their drugs. The growth in varieties of controlled release drugs and nanotechnology has also shaped the options these companies can choose from. Among some of the emerging drug delivery options are nanotechnology and orodispersible technology in which the medicine dissolves when it gets into contact with saliva for children and older patients who may have problems swallowing.